BioLineRx Ltd. – NASDAQ:BLRX
BioLineRx Ltd. stock price today
$3.96
+3.73
+1687%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
BioLineRx Ltd. stock price monthly change
-68.89%
month
BioLineRx Ltd. stock price quarterly change
-68.89%
quarter
BioLineRx Ltd. stock price yearly change
-86.13%
year
BioLineRx Ltd. key metrics
Market Cap | 18.79M |
Enterprise value | 51.04M |
P/E | -2.3 |
EV/Sales | N/A |
EV/EBITDA | -2.25 |
Price/Sales | N/A |
Price/Book | 0.96 |
PEG ratio | -0.03 |
EPS | -0.75 |
Revenue | N/A |
EBITDA | -42.00M |
Income | -49.14M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBioLineRx Ltd. stock price history
BioLineRx Ltd. stock forecast
BioLineRx Ltd. financial statements
| Jun 2023 | 0 | -18.54M | |
|---|---|---|---|
| Sep 2023 | 0 | -16.02M | |
| Dec 2023 | 4.8M | -13.88M | -289.25% |
| Mar 2024 | 6.85M | -696K | -10.15% |
| 2027 | 54.82M | -1.92M | -3.51% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2022-09-30 | -0.20454 | -0.15 |
|---|---|---|
| 2022-11-15 | -0.15 | -0.15 |
| 2023-03-22 | -0.09 | -0.09 |
| Jun 2023 | 58936000 | 37.88M | 64.28% |
|---|---|---|---|
| Sep 2023 | 52855000 | 39.72M | 75.15% |
| Dec 2023 | 63925000 | 50.70M | 79.31% |
| Mar 2024 | 51600000 | 38.54M | 74.69% |
| Jun 2023 | -9.68M | 11.1M | -134K |
|---|---|---|---|
| Sep 2023 | -9.90M | 4.09M | 3.49M |
| Dec 2023 | 4.99M | -20.39M | 11.74M |
| Mar 2024 | -14.10M | 16.68M | -894K |
BioLineRx Ltd. alternative data
| Aug 2023 | 49 |
|---|---|
| Sep 2023 | 49 |
| Oct 2023 | 49 |
| Nov 2023 | 49 |
| Dec 2023 | 49 |
| Jan 2024 | 49 |
| Feb 2024 | 49 |
| Mar 2024 | 49 |
| Apr 2024 | 49 |
| May 2024 | 79 |
| Jun 2024 | 79 |
| Jul 2024 | 79 |
BioLineRx Ltd. other data
0.07%
-0.73%
of BLRX is owned by hedge funds
511.62K
-5.20M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 17 Oct 2019 Issue date: 10 Mar 2022 |
Application Filling date: 17 Oct 2019 Issue date: 13 Jan 2022 |
Application Filling date: 25 Sep 2019 Issue date: 4 Nov 2021 |
Grant Filling date: 23 Feb 2017 Issue date: 4 May 2021 |
Application Filling date: 27 May 2019 Issue date: 29 Apr 2021 |
Application Filling date: 31 Aug 2020 Issue date: 17 Dec 2020 |
Grant Filling date: 14 Jul 2016 Issue date: 29 Sep 2020 |
Application Filling date: 5 May 2020 Issue date: 24 Sep 2020 |
Application Filling date: 5 May 2020 Issue date: 24 Sep 2020 |
Application Filling date: 5 May 2020 Issue date: 24 Sep 2020 |
| Quarter | Transcript |
|---|---|
| Q1 2024 28 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 26 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 20 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 30 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA (1960) Chief Executive Officer | $555,000 |
Dr. Ella Sorani (1968) Chief Devel. Officer | $357,000 |
Dr. Abi Vainstein-Haras M.D. (1975) Chief Medical Officer | $347,000 |
Ms. Mali Zeevi CPA, CPA (1976) Chief Financial Officer | $314,000 |
BioLineRx: Weighing Aphexda's Breakthrough Against Financial Challenges
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7B
Assessing BioLineRx As A Buy After Drug Approval
BioLineRx: PDUFA Catalyst And PDAC Advancement Make This Worth A Look
Week In Review: Henlius Signs $196 Million Deal For 2 Oncology Bifunctional Sialidase Candidates
2021 Top Idea Contest - New Ideas
BioLineRx: A Top Candidate For A Takeover Before 2022 Ends
-
What's the price of BioLineRx Ltd. stock today?
One share of BioLineRx Ltd. stock can currently be purchased for approximately $3.96.
-
When is BioLineRx Ltd.'s next earnings date?
Unfortunately, BioLineRx Ltd.'s (BLRX) next earnings date is currently unknown.
-
Does BioLineRx Ltd. pay dividends?
No, BioLineRx Ltd. does not pay dividends.
-
How much money does BioLineRx Ltd. make?
BioLineRx Ltd. has a market capitalization of 18.79M. BioLineRx Ltd. made a loss 60.61M US dollars in net income (profit) last year or -$0.09 on an earnings per share basis.
-
What is BioLineRx Ltd.'s stock symbol?
BioLineRx Ltd. is traded on the NASDAQ under the ticker symbol "BLRX".
-
What is BioLineRx Ltd.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of BioLineRx Ltd.?
Shares of BioLineRx Ltd. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BioLineRx Ltd.'s key executives?
BioLineRx Ltd.'s management team includes the following people:
- Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA Chief Executive Officer(age: 65, pay: $555,000)
- Dr. Ella Sorani Chief Devel. Officer(age: 57, pay: $357,000)
- Dr. Abi Vainstein-Haras M.D. Chief Medical Officer(age: 50, pay: $347,000)
- Ms. Mali Zeevi CPA, CPA Chief Financial Officer(age: 49, pay: $314,000)
-
How many employees does BioLineRx Ltd. have?
As Jul 2024, BioLineRx Ltd. employs 79 workers, which is 61% more then previous quarter.
-
When BioLineRx Ltd. went public?
BioLineRx Ltd. is publicly traded company for more then 14 years since IPO on 27 Jul 2011.
-
What is BioLineRx Ltd.'s official website?
The official website for BioLineRx Ltd. is biolinerx.com.
-
How can i contact BioLineRx Ltd.?
BioLineRx Ltd. can be reached via phone at +972 8 642 9100.
BioLineRx Ltd. company profile:
BioLineRx Ltd.
biolinerx.comExchange:
NASDAQ
Full time employees:
79
Industry:
Biotechnology
Sector:
Healthcare
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Modi’in Technology Park
Hevel Modi'in, 7177871
Hevel Modi'in, 7177871
CIK: 0001498403
ISIN: US09071M2052
CUSIP: 09071M205
